A mathematical model predicting anti‐hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B

The determination of serum levels of antibodies against hepatitis B virus surface antigen (anti‐HBs) after hepatitis B vaccination is currently the only simple test available to predict the decay of protection and to plan the administration of booster doses. A total of 3085 vaccine recipients of pla...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental immunology 1999-04, Vol.116 (1), p.121-126
Main Authors: HONORATI, M. C., PALARETI, A., DOLZANI, P., BUSACHI, C. A., RIZZOLI, R., FACCHINI, A.
Format: Article
Language:English
Subjects:
Algorithms
antibody kinetic
anti‐HBs
Biological and medical sciences
Cohort Studies
Hepatitis B
Hepatitis B - prevention & control
Hepatitis B Antibodies - blood
Hepatitis B Antibodies - metabolism
Hepatitis B Surface Antigens - therapeutic use
hepatitis B vaccination
Hepatitis B Vaccines - therapeutic use
Hepatitis B virus
Human viral diseases
Humans
Infectious diseases
Kinetics
Medical sciences
Models, Theoretical
Original
plasma‐derived vaccine
recombinant vaccine
Vaccination
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The determination of serum levels of antibodies against hepatitis B virus surface antigen (anti‐HBs) after hepatitis B vaccination is currently the only simple test available to predict the decay of protection and to plan the administration of booster doses. A total of 3085 vaccine recipients of plasma‐derived and recombinant vaccine have been followed for 10 years to determine the kinetics of anti‐HBs production and to construct a mathematical model which could efficiently predict the anti‐HBs level decline. The anti‐HBs peak level was reached 68 days after the last dose of recombinant vaccine and 138 days after the last dose of plasma‐derived vaccines. The age of vaccinees negatively influenced the anti‐HBs levels and also the time necessary to reach the anti‐HBs peak. A bilogarithmic mathematical model (log10 level, log10 time) of anti‐HBs decay has been constructed on a sample of recombinant vaccine recipients and subsequently validated on different samples of recombinant or plasma‐derived vaccine recipients. Age, gender, type of vaccine (recombinant or plasma‐derived), number of vaccine doses (three or four) did not influence the mathematical model of antibody decay. The program can be downloaded at the site: http://www2.stat.unibo.it/palareti/vaccine.htm. Introducing an anti‐HBs determination obtained after the peak, the program calculates a prediction of individual anti‐HBs decline and allows planning of an efficient booster policy.
ISSN:0009-9104
1365-2249
DOI:10.1046/j.1365-2249.1999.00866.x